Autopsy report · NCT02156115
Characterization of the Pathogenesis of Primary and Secondary Lymphatic Disorders
Cause of deathSlow enrollment
“Study closed before total enrollment met.”
Life of this trial
- Registered 10 months before it started.
- Ran for about 9 years before it stopped.
- 14 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- Sponsor type
- US National Institutes of Health
- Conditions
- Lymphangiomatosis; Lymphedema; Lymphangiectasia; Pulmonary Lymphangiectasia
- Participants
- 14
- Sites
- 1
- Countries
- United States
Trials that died the same way
- Reconstruction Flaps for Nasal Surgical Wounds RCT
“Study closed before enrollment could begin.” - Ruxolitinib for Early Lung Dysfunction After Hematopoietic Stem Cell Transplant
“Study closed due to slow enrollment.” - Tolfenamic Acid, Gemcitabine and Radiation for Locally Advanced or Metastatic Pancreatic Cancer Requiring Radiation
“The study closed prior to enrolling any participants.” - A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer
“Study closed to enrollment due to low accrual.” - Assessment of Current Biomarker Testing Practices for Common Solid Cancers in Precision Oncology in the Community Setting
“Study closed before patients enrolled”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.